Liver cancer research focuses on understanding causes, improving early detection, and developing more effective treatments, especially for hepatocellular carcinoma, the most common type.

Chronic hepatitis B and C infections, alcohol-related liver disease, and non alcohol related fatty liver disease are major risk factors, often leading to cirrhosis and then cancer. Obesity, diabetes, and aflatoxin exposure also play important roles. Research is clarifying how chronic inflammation, oxidative stress, and genetic and epigenetic alterations drive malignant transformation of liver cells.

Early detection remains difficult because symptoms appear late. Studies are evaluating blood biomarkers such as alpha fetoprotein and newer panels of proteins, DNA alterations, and circulating tumor cells to improve screening in high risk groups. Advanced imaging methods are being refined to better characterize small nodules and guide treatment decisions.

On the treatment side, liver transplantation and surgical resection can be curative but only for selected patients. Research is improving criteria for transplant eligibility, organ allocation, and outcomes. Local ablative therapies and transarterial chemoembolization extend options for patients with intermediate stage disease.

Systemic therapy has shifted toward targeted drugs and immunotherapy. Multikinase inhibitors and monoclonal antibodies that block angiogenesis have modestly improved survival. Immune checkpoint inhibitors targeting PD 1, PD L1, and CTLA 4 show promising responses in some patients, particularly in combination regimens. Ongoing trials are testing combinations of immunotherapy, targeted agents, and locoregional treatments, as well as exploring biomarkers that predict which patients will benefit.

Prevention research emphasizes vaccination against hepatitis B, antiviral treatment of hepatitis B and C, and interventions for obesity and fatty liver disease to reduce future liver cancer burden.